Form 4: Citius Pharmaceuticals CFO Jaime Bartushak Reports Stock Option Grant and Holdings
SEC Form 4 Filing
Citius Pharmaceuticals' Chief Financial Officer, Jaime Bartushak, reported the grant of 350,000 stock options and existing holdings of various other stock options.
Summary
- Jaime Bartushak, the Chief Financial Officer of Citius Pharmaceuticals, reported a transaction on November 7, 2024.
- The transaction involved the grant of 350,000 stock options with an exercise price of $0.38.
- These options vest in three equal installments on the one, two, and three-year anniversaries of the vesting commencement date, contingent on continuous service.
- The report also details existing holdings of various stock options with different exercise prices and vesting schedules.
- These existing options range in price from $0.67 to $10.50 and have various expiration dates.
Sentiment
Score: 7
Explanation: The document is a routine disclosure of stock option grants, which is generally neutral to positive as it aligns management with shareholder interests. There is no indication of any negative sentiment.
Positives
- The grant of stock options to the CFO aligns his interests with the company's long-term performance.
- The vesting schedule of the new options encourages continued service from the CFO.
- The report provides transparency into the CFO's holdings of company stock and options.
Risks
- The value of the stock options is dependent on the future performance of Citius Pharmaceuticals' stock price.
- The vesting of the new options is contingent on the CFO's continued employment with the company.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies. It provides transparency into the stock holdings of company insiders.
Comparison to Industry Standards
- Stock option grants are a common form of compensation for executives in the pharmaceutical industry.
- The vesting schedules and exercise prices are typical for such grants.
- Companies like Amgen, Gilead, and Regeneron also use stock options as part of their executive compensation packages.
Stakeholder Impact
- Shareholders can view this as a positive sign that the CFO's interests are aligned with the company's success.
- Employees may see this as a standard practice for executive compensation.
Key Dates
| Date | Description |
|---|---|
| 10/04/2022 | Stock options granted with a $1.25 exercise price. |
| 07/06/2026 | Expiration date for stock options with a $10.50 exercise price. |
| 09/15/2027 | Expiration date for stock options with a $3.45 exercise price. |
| 09/04/2028 | Expiration date for stock options with a $1.62 exercise price. |
| 10/08/2029 | Expiration date for stock options with a $0.67 exercise price. |
| 10/06/2030 | Expiration date for stock options with a $1.01 exercise price. |
| 07/22/2031 | Expiration date for stock options with a $2.00 exercise price. |
| 10/11/2031 | Expiration date for stock options with a $2.04 exercise price. |
| 10/04/2032 | Expiration date for stock options with a $1.25 exercise price. |
| 10/10/2033 | Expiration date for stock options with a $0.70 exercise price. |
| 11/07/2024 | Date of the new stock option grant with a $0.38 exercise price. |
| 11/07/2034 | Expiration date for stock options with a $0.38 exercise price. |
| 11/12/2024 | Date of the report filing. |
Keywords
stock options, Citius Pharmaceuticals, Jaime Bartushak, CFO, insider trading, executive compensation, equity, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.